A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT04732221

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04732221
  • EU CT 2022-500877-15-00
  • WHO UTN U1111-1278-4977
  • EudraCT 2020-001108-40
Other papers using this trial's data
  • MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study The European respiratory journal, 2024-11 DOI, PubMed 39255991, PMC11561403 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russia, Sweden, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04732221. Randomized; triple masking; primary purpose treatment. Start 2021-05-19 (actual); primary completion 2024-01-04 (actual). Results posted on 2025-02-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
Condition
Pulmonary Arterial Hypertension
Condition
Hypertension, Pulmonary
Intervention (Drug)
Frespaciguat
Intervention (Drug)
Placebo to Frespaciguat
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct04732221
Content hash
a8c0578e5d0a9d02f58c479aa9787ad5c963432e4a6f53e26c5ef1dc0d539406